Skip to main content
. 2023 Apr 28;25(11):3188–3202. doi: 10.1007/s12094-023-03187-5

Fig. 1.

Fig. 1

Anagliptin enhances anti-programmed cell death ligand 1 (PD-L1)-mediated Lewis lung cancer (LLC) tumor suppression. a, Schematic of anagliptin and anti-PD-L1 treatments. b, Representative image of LLC subcutaneous tumors in each group. c, The volume of subcutaneous LLC tumors from each group for the indicated times (mean ± S.E., n = 5/group). *, P < 0.05; ***, P < 0.01